Clinical Study

Vnc-152-102 - An Open-Label, Multicenter Phase 1 Dose Escalation Study To Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, And Maximum Tolerated Dose Of Vip152 In Subjects With Relapsed/Refractory Chronic Lymphocytic Le

Posted Date: Mar 31, 2022

  • Investigator: Emily Curran
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).


To Be Eligible: Patients With A Histologically Or Cytologically Confirmed Solid Tumor Or Aggressive Nhl Who Are Refractory To Or Have Exhausted All Available Therapies With Myc Expression Or Known C-Myc Amplification/Alterations, Adequate Bone Marrow, Liver, And Renal Functions, Eastern Cooperative Oncology Group (Ecog) Performance Status Of 0 To 2, No Active Clinically Serious Infections Of Events > Grade 2, No Subjects Who Have New Or Progressive Brain Or Meningeal Or Spinal Metastases, No Anticancer Chemotherapy Or Immunotherapy During The Study Or Within 1 Weeks Prior To The First Dose Of Study Drug, No Major Surgery Or Significant Trauma Within 4 Weeks Before The First Dose Of Study Drug, No Allogeneic Bone Marrow Transplant Or Stem Cell Rescue Within 4 Months Before First Dose Of Study Drug; Patients Must Have Completed Immunosuppressive Therapy Before Enrollment.


Phase 1, Leukemia, Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.